LNSRHealthcare · Medical DevicesLNSR Stock Forecast: LENSAR, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering LENSAR, Inc. hold a median 12-month price target of $8.5 — +58.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 1 Aug 2026 — in the lower half.
LNSR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores LENSAR, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (80): Smaller than most of the companies we track.
Momentum (5): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own LENSAR, Inc. — and when they’d sell — is the membership.
LNSR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LNSR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +58.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Mar 2026 | BTIG | Upgrade | Buy | $10 |
| 24 Mar 2025 | Lake Street | Downgrade | Hold | — |
| 28 Feb 2025 | Lake Street | Maintains | Buy | — |
| 19 Mar 2024 | Lake Street | Initiates | Buy | — |
| 22 Nov 2021 | BTIG | Initiates | Buy | — |
| 24 Feb 2021 | SVB Leerink | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LNSR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
LENSAR, Inc. (LNSR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −1.8×
- Price / sales
- 1.1×
- Price / book
- 5.6×
- EV / EBITDA
- −3.1×
Cheaper than 84% of US stocks
Cheaper than 68% of US stocks
Cheaper than 19% of US stocks
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- −5.2%
- Earnings growth (YoY)
- —
- Gross margin
- 47.5%
- Operating margin
- −15.9%
- Net margin
- 50.9%
Higher than 21% of US stocks
Higher than 61% of US stocks
Higher than 24% of US stocks
Higher than 96% of US stocks
- Return on equity
- 362.5%
- Return on assets
- −22.6%
- Dividend yield
- —
Higher than 99% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
LNSR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LNSR appears on the weeks it earns a place.
Frequently asked questions about LNSR stock
What is the LNSR stock price forecast for 2026-2027?
The 2 Wall Street analysts covering LENSAR, Inc. have a median 12-month price target of $8.5, with estimates ranging from $7 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LNSR stock a buy right now?
Of the 2 analysts covering LENSAR, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LENSAR, Inc. 40 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LNSR?
As at 1 Aug 2026, LENSAR, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).
Will LNSR stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +58.0% from the last close, and Ticker Nerd's factor model ranks LENSAR, Inc. 40 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LNSR stock forecast for 2030?
No analyst covering LENSAR, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNSR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $10 over the next 12 months.
How has LNSR stock performed over the past year?
LENSAR, Inc. returned -57.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does LENSAR, Inc. do?
Lensar Inc. is renowned for its advancement in femtosecond laser technology, specifically designed for cataract surgery.
About LENSAR, Inc.
Lensar Inc. is renowned for its advancement in femtosecond laser technology, specifically designed for cataract surgery. As a medical technology company, Lensar focuses predominantly on offering innovative solutions that enhance the precision and effectiveness of cataract surgery procedures. Its flagship product, the Lensar Laser System, is engineered to provide surgeons with superior imaging and laser guidance to perform precise cataract surgeries, thereby improving surgical outcomes and patient safety. Lensar operates at the intersection of healthcare and technology, influencing the ophthalmology sector significantly. By providing state-of-the-art laser systems, the company plays a critical role in advancing surgical standards and patient care in the rapidly growing field of eye health. Headquartered in Orlando, Florida, Lensar continues to contribute to medical technology through continuous research and development, reinforcing its position as a key player in promoting cutting-edge surgical solutions globally.
CEO Mr. Nicholas T. Curtis · 150 employees · United States · https://www.lensar.com